Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.695 USD | -26.30% | -7.71% | -36.06% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.03M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.17
x | P/E ratio 2025 * |
-0.09
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.05% |
Latest transcript on Cyclacel Pharmaceuticals, Inc.
1 day | +56.96% | ||
1 week | +17.34% | ||
Current month | +9.01% | ||
1 month | +5.11% | ||
3 months | +11.65% | ||
6 months | -74.19% | ||
Current year | -13.86% |
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-12-31 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 06-02-28 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1.695 | -26.30% | 2 925 266 |
24-04-24 | 2.3 | +28.49% | 551,102 |
24-04-23 | 1.79 | +2.29% | 28,374 |
24-04-22 | 1.75 | -1.69% | 25,527 |
24-04-19 | 1.78 | -3.78% | 10,391 |
Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.86% | 3.03M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.72% | 22.2B | |
-16.53% | 21.23B | |
-9.05% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- CYCC Stock